Aveanna raised its full-year adjusted EBITDA target to more than $374 million from more than $365 million. Cost discipline and 10.2% growth in private duty hours drove the quarter.
Aveanna Healthcare Holdings Inc
AVAH at a Glance
- Market cap
- $2.9B
- P/E ratio
- 10.4
- Revenue (TTM)
- $2.6B
- Profit margin
- 10.6%
- EPS (TTM)
- $1.26
- 52-week range
- $6 – $15
- Street target
- $15.05
- Next report
- Nov 12, 2026
Headquartered in Atlanta, GA Fiscal year ends December NASDAQ: AVAH aveanna.com
About Aveanna Healthcare
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) is a diversified home care platform focused on medically complex, high-cost patient populations. It operates locations in 39 states. The company reports three segments:
- **Private Duty Services (PDS):** hourly nursing care. It generated about 83% of third-quarter 2026 revenue and is measured by hours and revenue rate per hour.
- **Home Health & Hospice (HHH):** Medicare-oriented home health episodes, admissions and hospice care.
- **Medical Solutions (MS):** delivery of enteral nutrition and other products to patients, measured by unique patients served.
Services for pediatric and adult patients include nursing, hospice, rehabilitation, occupational nursing in schools, therapy, day treatment center services and respite care. They are positioned as a lower-cost alternative to prolonged hospitalization. Revenue depends heavily on Medicaid, Medicare, managed care and private insurers. The company pursues Preferred Payor and Government Affairs strategies to improve reimbursement rates. It grows both organically and through acquisitions, which it integrates under the Aveanna brand. Total indebtedness is about $1.5 billion and is partially hedged with SOFR interest rate caps. Updated
Frequently Asked Questions
What does Aveanna Healthcare do?
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) is a diversified home care platform focused on medically complex, high-cost patient populations. It operates locations in 39 states.
What is the AVAH stock price target?
The Wall Street consensus 12-month price target for AVAH is $15.05.